Latest Hotspot

Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes

8 October 2023
3 min read

Kallyope, Inc., a biotech firm in clinical phase focusing on the identification and creation of innovative, orally-consumed, small-molecule treatments for conditions with significant unmet demand, has commenced its Phase 2 experiment to assess K-757 and K-833. These innovative oral nutrient receptor stimulants are being examined for their potential in combating obesity and Type 2 diabetes.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

The purpose of the K-757 P006 trial is to establish the effectiveness, safety, and patient acceptance of these new treatments for obesity, a serious health issue that is becoming more prevalent in the United States. Losing weight can greatly contribute towards managing severe health risks such as Type 2 diabetes, cardiovascular disease, and elevated cholesterol. 

Although modern medical treatments are available for obesity and diabetes, only 2 percent of U.S. obesity patients are treated medically. Wide access to helpful, user-friendly, and easily tolerated oral medicines will be a crucial move in attaining this underserved necessity more inclusively.

The immediate need for oral, user-friendly, more tolerable, and cost-effective solutions to address the significant unmet requirements for those suffering from obesity is evident," stated Jay Galeota, Kallyope's president and CEO. "K-757 and K-833 introduce an unprecedented oral strategy that could significantly improve treatment possibilities for those affected by obesity and Type 2 diabetes.”

"It is essential to discover new treatments that are safe, well-accepted, and effective for losing weight, either as solo drugs or in conjunction with others," Brett Lauring, M.D., Ph.D., Chief Medical Officer of Kallyope said. “The community of obesity patients is extremely diverse and is just starting to be studied, and there is a need for a variety of treatments from differing classes to address their unique situations.”

The Kallyope team has made significant headway in moving these pioneering substances from research to clinical trials,” shared Nancy Thornberry, founding CEO and head of Research and Development at Kallyope. “K-757 and K-833’s mode of action is fundamentally unlike the GLP-1 agonists currently available. This approach is expected to be beneficial for weight loss and blood sugar regulation and might be easier to administer and accept than GLP-1s.”

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, targets, organizations, clinical trials, clinical results, and drug patents related to this indication.

According to the data provided by the Synapse Database, As of October 5, 2023, there are 859 investigational drugs for the Obesity, including 236 targets, 604 R&D institutions involved, with related clinical trials reaching 15185and as many as 166371 patents.

K-757 and K-833 serve as oral nutrient receptor stimulants that intensify the body's innate metabolic messages to provoke the production of several hunger-controlling hormones like GLP-1, along with various other scientifically confirmed hormones such as PYY and CCK. The impact this has on these naturally occurring hunger-controlling hormones liken to what is observed post bariatric surgery. These are currently the sole recognized oral nutrient receptor stimulants under research for managing obesity.

图形用户界面, 文本, 应用程序

描述已自动生成

New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
Latest Hotspot
3 min read
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
8 October 2023
A new research indicates that Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, elicits robust and long-lasting immunity in lab animals.
Read →
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
Latest Hotspot
3 min read
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
8 October 2023
Takeda announced U.S. FDA approval for ENTYVIO®(vedolizumab) subcutaneous delivery as a maintenance treatment for moderate to severe ulcerative colitis in adults, after initial intravenous therapy.
Read →
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
Latest Hotspot
3 min read
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
8 October 2023
Gamida Cell Ltd. has declared that the initial patient has been subjected to a stem cell transplantation procedure using Omisirge (omidubicel-onlv).
Read →
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
Latest Hotspot
4 min read
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
8 October 2023
Abeona Therapeutics Inc. has reported that they've lodged a BLA with U.S. FDA with a request to endorse EB-101.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.